OnabotulinumtoxinA Improves Health-Related Quality of Life in Patients With Urinary Incontinence Due to Idiopathic Overactive Bladder: A 36-Week, Double-Blind, Placebo-Controlled, Randomized, Dose-Ranging Trial

Fowler, Clare J.; Auerbach, Stephen M.; Ginsberg, David A.; Hale, Douglass S.; Radziszewski, Piotr; Rechberger, Tomasz; Patel, Vaishali; Zhou, Jihao; Thompson, Catherine; Kowalski, Jonathan W.

doi:10.1016/j.eururo.2012.03.005

Cited by 77 publications

(60 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Data have been given about changes in QoL due to treatment and about PVR and UTIs at week 12, which were less than 50 ml and 15.5-20.4%, respectively. Also, in other published studies, local anesthesia has been used to treat patients with idiopathic OAB, in an outpatient setting (11)(12)(13)(14)(15). Nevertheless, all these studies did not mention patients' satisfaction with treatment, but they often report on satisfaction about changes in urinary symptoms and QoL.…”

Section: Discussionmentioning

confidence: 99%

Onabotulinumtoxina Intravesical Treatment in Patients Affected by Overactive Bladder Syndrome: Best Practice in Real-Life Management

Giannantoni

Proietti²,

Costantini

et al. 2015

Urologia

View full text Add to dashboard Cite

Purpose:We evaluated intradetrusorial OnabotulinumtoxinA (Onabot/A) treatment protocols in patients with idiopathic overactive bladder (OAB), in order to assess the care of patients before, during and after treatment. Methods: In 64 OAB patients injected with Onabot/A, we reviewed the length of the hospital stay, frequency of catheterization, frequency of intraoperative and postoperative complications, and patients' satisfaction to the proposed treatment protocol (as assessed by VAS). We also compared the results of the 3-day voiding diary, uroflowmetry with postvoid residual urine (PVR) and VAS to score the bother of urinary symptoms on quality of life (QoL) before and after treatment. Results: Twenty-one patients were firstly treated in an 'inpatient' setting. The mean ± SD duration of hospitalization and catheterization was 39.4 ±12.6 and 37.8 ± 10.6 h, respectively. The mean ± SD VAS values of treatment satisfaction and of bother of urinary symptoms on QoL were 6.3 ± 1.1 and 8.2 ± 1.3, respectively. The mean ± SD PVR value was 74.3 ± 15.2 ml. Frequency of UTIs was 2.4 ± 1.6. Forty-three patients were treated on an outpatient basis; the mean ± SD duration of catheterization, the 'outpatient' stay and the mean ± SD frequency of UTIs were lower than those of patients treated in an inpatient setting. The mean ± SD VAS value to score QoL was high. Conclusions: Intradetrusorial Onabot/A injection is a simple and fast procedure that can be easily carried on in an outpatient setting under local anesthesia, with low rates of intraoperative and postoperative complications.

show abstract

Section: Discussionmentioning

confidence: 99%

Onabotulinumtoxina Intravesical Treatment in Patients Affected by Overactive Bladder Syndrome: Best Practice in Real-Life Management

Giannantoni

Proietti²,

Costantini

et al. 2015

Urologia

View full text Add to dashboard Cite

show abstract

“…With this dose the response rate (in the reports usually defined as >50% improvement or 'improved' or 'greatly improved' on Treatment Benefit Scales) is in excess of 60% in most studies (range 37-70%), typically with a 20-50% reduction in incontinence episodes (i.e. about 3 fewer leaks per 24 hours), 23-55% of patients achieving continence, and statistically significant improvement in quality of life measures [2][3][4][6][7][8] (Table 3). The response rate in our study is somewhat lower at 43% at one month and 36% at three months, and while there was statistically significant reduction in incontinence episodes (p=0.01) and leakage (p=0.025), the numbers are lower than those reported after cystoscopic injection.…”

Section: Comparison With Cystoscopic Injectionmentioning

confidence: 99%

“…With this dose the response rate is above 60% in most studies (range 37-70%, Table 3), typically with a 20-50% reduction in incontinence episodes (i.e. 2-3 fewer leaks per 24 hours), 23-55% of patients achieving continence, and a statistically significant improvement in quality of life measures [2][3][4][6][7][8] . The main complications are a 5-36% risk of UTI [2][3][4][5][6]9] and a 4-11% risk of impaired bladder emptying requiring catheterization [1,3,4,6,9] .…”

Section: Introductionmentioning

confidence: 99%

Intravesical Electromotive Botulinum Toxin in Women with Overactive Bladder – A Pilot Study

2017

ARC Journal of Gynecology and Obstetrics

View full text Add to dashboard Cite

“…Only 3 RCTs were included in their review. Since the publication of their review, various new RCTs have been published which included many large sample size studies about botulinum toxin used for idiopathic OAB [6,7,8,9,10,11]. In this paper, we attempt to summarize the data from all RCTs to assess the efficacy and safety of botulinum toxin-A in the management of idiopathic OAB.…”

Section: Introductionmentioning

confidence: 99%

Botulinum Toxin-A Injections for Idiopathic Overactive Bladder: A Systematic Review and Meta-Analysis

Yu¹,

Wang²,

Liu³

et al. 2013

Urol Int

View full text Add to dashboard Cite

Objective: To review the current evidence on the efficacy and safety of botulinum toxin-A in the management of idiopathic overactive bladder (OAB). Methods: A systematic search of PubMed, Embase and the Cochrane Central Search Library was performed. All randomized controlled trials comparing botulinum toxin-A with placebo, different doses and injection techniques, in patients with idiopathic OAB was included. The analyzed outcomes were quantification of symptoms, urodynamic outcomes, quality of life and adverse events. Result: A total of 1,020 participants from 12 randomized controlled trials were included. Botulinum toxin-A was associated with less urinary frequency, less incontinence episodes, improvement in quality of life, higher post-void residual-related catheterization and higher urinary tract infection. Doses of 100-300 U were not consistently differentiated from each other in voiding diary, quality of life and urge urinary incontinence. No statistically significant difference was seen between bladder body and bladder base, bladder body and bladder body plus trigone in urinary retention and urinary tract infection. Conclusion: Botulinum toxin-A is associated with significant improvement in OAB symptoms in patients with idiopathic OAB. However, there is a higher incidence of postoperative urinary retention and urinary infection compared to placebo. Low-dose botulinum toxin-A seems to be the optimum dose that appropriately balances the benefits with adverse events. Trigone inclusion seems as safe and effective as trigone-sparing injection.

show abstract

OnabotulinumtoxinA Improves Health-Related Quality of Life in Patients With Urinary Incontinence Due to Idiopathic Overactive Bladder: A 36-Week, Double-Blind, Placebo-Controlled, Randomized, Dose-Ranging Trial

Cited by 77 publications

References 21 publications

Onabotulinumtoxina Intravesical Treatment in Patients Affected by Overactive Bladder Syndrome: Best Practice in Real-Life Management

Onabotulinumtoxina Intravesical Treatment in Patients Affected by Overactive Bladder Syndrome: Best Practice in Real-Life Management

Intravesical Electromotive Botulinum Toxin in Women with Overactive Bladder – A Pilot Study

Botulinum Toxin-A Injections for Idiopathic Overactive Bladder: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About